Bio-Rad Laboratories, Inc.
BIO
$265.26
$0.940.36%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.33% | -2.46% | -3.92% | -5.15% | -7.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.33% | -2.46% | -3.92% | -5.15% | -7.46% |
| Cost of Revenue | 1.86% | -3.07% | -4.64% | -6.80% | -7.46% |
| Gross Profit | -2.19% | -1.92% | -3.29% | -3.73% | -7.46% |
| SG&A Expenses | -1.49% | -3.85% | -3.55% | -3.35% | -4.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.16% | -0.68% | -1.74% | -3.61% | -7.27% |
| Operating Income | -23.31% | -14.83% | -18.94% | -15.07% | -8.66% |
| Income Before Tax | 126.02% | -519.65% | -175.56% | -436.92% | -225.36% |
| Income Tax Expenses | 132.40% | -382.49% | -134.15% | -711.32% | -291.29% |
| Earnings from Continuing Operations | 124.08% | -571.34% | -189.38% | -388.83% | -209.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.08% | -571.34% | -189.38% | -388.83% | -209.46% |
| EBIT | -23.31% | -14.83% | -18.94% | -15.07% | -8.66% |
| EBITDA | -14.39% | -9.13% | -12.05% | -9.75% | -4.93% |
| EPS Basic | 125.03% | -637.14% | -202.82% | -376.52% | -216.47% |
| Normalized Basic EPS | -21.16% | -11.59% | -19.31% | -14.20% | -1.94% |
| EPS Diluted | 124.94% | -634.96% | -202.54% | -367.41% | -214.24% |
| Normalized Diluted EPS | -21.08% | -11.50% | -19.14% | -13.97% | -1.84% |
| Average Basic Shares Outstanding | -3.22% | -3.01% | -3.41% | -3.47% | -3.01% |
| Average Diluted Shares Outstanding | -3.31% | -3.10% | -3.61% | -3.71% | -3.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |